---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-24-000004"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T07:57:15.887894+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M

## Summary
- Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.
- Up to $25M in additional milestone payments payable in cash or stock over next two years.
- Veracyte to issue up to 2,698,349 shares as stock consideration; cash in lieu for non-accredited investors.
- SEC granted partial waiver from certain financial statement requirements under Rule 3-13.
- Closing occurred on February 5, 2024; audited C2i financials to be filed within 71 days.

## SEC filing metadata
- accession: 0001384101-24-000004
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 9.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/0001384101-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/vcyt-20240205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-24-000004
- JSON: https://secwatch.observer/filing/0001384101-24-000004.json
- Plain text: https://secwatch.observer/filing/0001384101-24-000004.txt

## Key facts
- M&A Transactions
  VERACYTE, INC. completed an acquisition involving C2i Genomics, Inc. for $70.0 million (closed 2024-02-05).
  - Action: acquisition
  - Counterparty: C2i Genomics, Inc.
  - Consideration: $70.0 million
  - Closing: 2024-02-05
  source text: On February 5, 2024 (the “Closing Date”), Veracyte, Inc., a Delaware corporation (“Veracyte”), completed its previously announced acquisition of C2i Genomics, Inc., a Delaware corporation (“C2i Genomics”), for a purchase price of $70.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000004/0001384101-24-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.